Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention

AIDS

Volumn 26, Issue 7, 2012, Pages

  Van Der Straten, Ariane ^a   Van Damme, Lut ^b   Haberer, Jessica E ^c   Bangsberg, David R ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

antiretrovirals; biomedical HIV prevention trials; microbicide; pre exposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MICROBICIDE; PLACEBO; TENOFOVIR DISOPROXIL;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG EXPOSURE; DRUG TOLERABILITY; HERPES SIMPLEX VIRUS 2; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; THERAPY EFFECT; VIRUS LOAD; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, ORAL; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; PHOSPHONIC ACIDS; RISK FACTORS; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84860014826     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283522272     Document Type: Article

References (55)

1. FHI statement on the FEM-PrEP HIV prevention study: FHI to initiate orderly closure of FEM-PrEP. In. http://www.fhi360.org/en/AboutFHI/Media/ Releases/FEM-PrEP-statement041811.htm FHI 360; 2011.
2. Microbicide trials network statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women. In. http://www.mtnstopshiv.org/node/3619: Microbicide Trials Network; 2011.
3. Microbicide trials network statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women. In. http://www.mtnstopshiv.org/node/3909: Microbicide Trials Network; 2011.
4. Mâsse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol 2009; 6: http://www.ete-online.com/content/6/1/5.
5. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Hub Clin Trials 2007; 2:e27.
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
7. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
8. Amico KR, Liu A, McMahan V, Anderson PL, Lama JR, Guanira J, et al. Adherence indicators and preexposure prophylaxis (PrEP) drug levels in the iPrEx study. In: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts.
9. Liu A, Huang Y, Defechereux P, McMahan V, Eden C, Guanira J, et al. Hair as a biological marker of daily oral preexposure prophylaxis (PrEP) adherence and tenofovir/emtricitabine (TFV/FTC) exposure in the Global iPrEx Study. In: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 2011; Rome, Italy.
10. FEM-PrEP fact sheet on adherence. In. http://www.fhi360.org//NR/ rdonlyres/ejz5zgddvcqscxov2rzcang7f74nnzz4v26bzcxrk6 vxjmm5dchnwb7sy7ct27h34djhi4bkv33hda/FEMPrEPFactSheet Adherence1.pdf: FHI 360.
11. Centers for Disease Control and Prevention (CDC). CDC trial and another major study find PrEP can reduce risk of HIV infection among heterosexuals. In. http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals.html: Centers for Disease Control and Prevention; 2011.
12. Baeten J, Celum C. Antiretroviral preexposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP study. In: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 2011; Rome, Italy.
13. Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. In. http://depts.washington.edu/uwicrc/research/studies/files/PrEP-PressRelease-UW- 13Jul2011.pdf: University of Washington International Clinical Research Center; 2011.
14. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
15. García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong M, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.
16. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartumand neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868. (Pubitemid 37130095)
17. Karim S, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011; 378:e23-e25.
18. Kashuba ADM, Patterson KB, Dumond JB, Cohen MS. Preexposure prophylaxis for HIV prevention: how to predict success. Lancet 2011 [Epub ahead of print].
19. Karim SSA, Kashuba ADM, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378:279-281.
20. Haberer JE, Baeten J, Celum C, Tumwesigye E, Katabira E, Krows M, et al. Near perfect early adherence to antiretroviral PrEP against HIV infection among HIV serodiscordant couples as determined by multiple measures: preliminary data from the partners PrEP study. In: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts.
21. Ware NC, Wyatt MA, Haberer J, Baeten J, Kintu A, Psaros C, et al. What's love got to do with it? Explaining adherence to oral antiretroviral preexposure prophylaxis (PrEP) for HIV serodiscordant couples. J Acquir Immune Defic Syndr (in press).
22. Montgomery E, van der Straten A, Torjesen K. 'Male involvement' in women and children's HIV prevention: challenges in definition and interpretation. J Acquir Immune Defic Syndr 2011; 57:e114-e116.
23. Montgomery ET, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav 2011; 15:959-969.
24. Amico KR, McMahan V, Goicochea P, Vargas L, Wolf E, Lama JR, et al. Developing an innovative approach to adherence counseling and assessment in a preexposure prophylaxis (PrEP) trial: next step counseling and neutral assessment in the iPrEx study. In: 5th International Conference on HIV Treatment Adherence; 2010; Miami, Florida.
25. MTN-003 study-specific procedure manual version 2: section 12. Counseling considerations. In. http://www.mtnstopshiv.org/node/1077: Microbicide Trials Network; 2011.
26. Hendrix C, Minnis A, Guddera V, Riddler S, Salata R, Nakabiito C, et al. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. In: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts.
27. Mutua G, Sanders EJ, Kamali A, Kibengo F, Mugo P, Anzala O, et al. Safety and adherence to intermittent emtricitabine/tenofovir for HIV preexposure prophylaxis (PrEP) in Kenya and Uganda. In: 17th International AIDS Conference; 2010; Vienna, Austria.
28. Van der Straten A, Montgomery E, Cheng H, Lutnick A, Musara P, Woodsong C. Preference between precoital and continuous use of Duet in Zimbabwe. In: International Microbicides Conference; 2010; Pittsburgh, Pennsylvania.
29. Vermund SH, Van Damme L. HIV prevention in women: next steps. Science 2011; 331:284.
30. Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 2008; 5:1-7.
31. Rudd P, Byyny RL, Zachary V, LoVerde ME, Titus C, Mitchell WD, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989; 46:169-176. (Pubitemid 19219953)
32. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 2006; 10:227-245.
33. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 2011; 66:240-250.
34. Patterson K, Prince H, Kraft E, Jenkins A, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
35. Schwartz JL, Rountree W, Kashuba ADM, Brache V, Creinin MD, Poindexter A, et al. A multicompartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011; 6:e25974.
36. Nuttall J, Kashuba A, Wang R, White N, Allen P, Roberts J, et al. The pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to Rhesus macaques. Antimicrob Agents Chemother 2011; 56:103-109.
37. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. AIDS 2006; 20:73-83. (Pubitemid 41818117)
38. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. AIDS 2009; 23:1595-1598.
39. Kaul R, Nagelkerke NJ, Kimani J, Ngugi E, Bwayo JJ, MacDonald KS, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. J Infect Dis 2007; 196:1692-1697. (Pubitemid 351411969)
40. Karim SA. Tenofovir gel and HIV transmission: insights from the CAPRISA 004 trial. In: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 2011; Rome, Italy.
41. Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011; 10:379-389.
42. Low N, Chersich MF, Schmidlin K, Egger M, Francis SC, van de Wijgert JHHM, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data metaanalysis. PLoS Med 2011; 8:e1000416.
43. Hilber AM, Francis SC, Chersich M, Scott P, Redmond S, Bender N, et al. Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis. PLoS One 2010; 5:e9119.
44. Mavedzenge SN, Weiss HA, Montgomery ET, Blanchard K, de Bruyn G, Ramjee G, et al. Determinants of differential HIV incidence among women in three southern African locations. J Acquir Immune Defic Syndr 2011; 58:89-99.
45. Rohan LC, Moncla BJ, Ayudhya RPKN, Cost M, Huang Y, Gai F, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010; 5:e9310.
46. Dezzutti CS, Rohan LC, Lynam JD, Wang L, Friend D. Tenofovir gel reformulation results in improved product safety for rectal application. In: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts.
47. Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 2005; 21:845-853. (Pubitemid 43150316)
48. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2011; 12:19-26.
49. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010; 31:79-97.
50. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008; 13:123-132. (Pubitemid 352000659)
51. Kearney BP, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy 2009; 29:924-929.
52. Stuart GS, Moses A, Corbett A, Phiri G, Kumwenda W, Mkandawire N, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. J Acquir Immune Defic Syndr 2011; 58:e40-e43.
53. Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav 2008; 12:677-684.
54. Abu-Raddad LJ, Longini IM Jr. No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 2008; 22:1055-1061. (Pubitemid 351769744)
55. Goodreau SM, Cassels S, Kasprzyk D, Montaño DE, Greek A, Morris M. Concurrent partnerships, acute infection and HIV epidemic dynamics among young adults in Zimbabwe. AIDS Behav 2010; 16:312-322.